Abstract:PPM1D (Protein Phosphatase Mg2+/Mn2+ Dependent 1D) is a protein phosphatase frequently mutated in clonal hematopoiesis (CH), therapy-related myeloid neoplasms, and solid tumors. PPM1D is best known as a negative regulator of the DNA damage response (DDR). Gain-of-function mutations in the terminal exon of PPM1D lead to a truncated, dominant form of PPM1D with preserved phosphatase activity. This stabilized, mutant protein leads to persistent dephosphorylation of PPM1D-targets including p53 and other key DDR proteins. Our lab previously demonstrated that mutant Ppm1d hematopoietic stem cells outcompete their wild-type (WT) counterparts in vivo following repeated cisplatin exposure. Given the prevalence of PPM1D mutations in CH and cancer, identifying novel candidates to exploit the genetic defects of these altered cells is an attractive therapeutic approach. We sought to identify genetic vulnerabilities of PPM1D-mutant cells by performing a whole-genome CRISPR dropout screen. Analysis of gene candidates that were essential for mutant cell survival, but not WT, identified superoxide dismutase 1 (SOD1) as the most essential gene in PPM1D-mutated leukemia cell lines. SOD1, a vital player in antioxidant defense, catalyzes the conversion of superoxide radicals into hydrogen peroxide and water. We showed that pharmacologic inhibition of SOD1 phenocopies the genetic deletion of SOD1. We determined that the dependency on SOD1 is due to increased oxidative stress and genomic instability caused by PPM1D mutations. Furthermore, SOD1 inhibition significantly increases reactive oxygen species and DNA breaks in the mutant cells leading to apoptosis. Overall, our work reveals SOD1 inhibition as a promising new synthetic lethal approach to target PPM1D-mutant clonal expansion in patients at high risk for developing therapy-related myeloid neoplasms.

Table S5 from Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations

Table S4 from Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations

Table S1 from Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations

Tabel S2 from Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations

Supplementary Figures, Results, and Methods from Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations

Signal-Oriented Pathway Analyses Reveal a Signaling Complex As a Synthetic Lethal Target for P53 Mutations

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Data 2 from Li–Fraumeni Syndrome–Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death

Modeling the Etiology of p53-mutated Cancer Cells

Integrated Multi‐omics Data Analyses for Exploring the Co‐occurring and Mutually Exclusive Gene Alteration Events in Colorectal Cancer

Supplementary Figure 5 from Ribosomal Protein S27-like, a P53-Inducible Modulator of Cell Fate in Response to Genotoxic Stress

Table S3 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy

Small-Molecule Modulators Of P53 Family Signaling And Antitumor Effects In P53-Deficient Human Colon Tumor Xenografts

Elucidating the chain of command: our current understanding of critical target genes for p53-mediated tumor suppression

Abstract 2956: High throughput RNAi screening of synthetic lethal genes interacting with the commonTP53mutation R175H

Differential gene expression in cells with different p53 mutations identifies genome-wide p53 targets and shows distinct modulation of cellular pathways in response to DNA damage

3232 – TARGETING SOD1 INDUCES SYNTHETIC LETHAL KILLING OF PPM1D-MUTANT LEUKEMIA CELLS

Integrative multiomic approaches reveal ZMAT3 and p21 as conserved hubs in the p53 tumor suppression network

p53 protein abundance is a therapeutic window across TP53 mutant cancers and is targetable with proximity inducing small molecules

Global Investigation of p53-induced Apoptosis Through Quantitative Proteomic Profiling Using Comparative Amino Acid-coded Tagging

P53 and Its Downstream Proteins As Molecular Targets of Cancer